Log In
Print this Print this

Probuphine, buprenorphine

  Manage Alerts
Collapse Summary General Information
Company Titan Pharmaceuticals Inc.
DescriptionSubcutaneous rod implant for continuous 6-month delivery of buprenorphine, a partial opioid agonist of the mu opioid receptor (MOR; OPRM1), using ProNeura technology
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentMarketed
Standard IndicationAddiction
Indication DetailsTreat opioid dependence
Regulatory Designation U.S. - Priority Review (Treat opioid dependence)
PartnerBraeburn Pharmaceuticals Inc.;
Knight Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today